Altered autonomic inputs as a cause of pancreatic β-cell amyloid

Medical Hypotheses

Volumn 82, Issue 1, 2014, Pages 49-53

  Watve, Milind ^a   Bodas, Arushi ^a   Diwekar, Manawa ^a  

^a INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; AMYLOID; GLUCOSE; INSULIN;

ADRENERGIC STIMULATION; ADRENERGIC SYSTEM; ARTICLE; CELL DEATH; CELL DESTRUCTION; CELL FREE SYSTEM; CELL PROLIFERATION; CHOLINERGIC SYSTEM; ENDOPLASMIC RETICULUM STRESS; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; NEGATIVE FEEDBACK; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; POLYMERIZATION; POSITIVE FEEDBACK; SECRETORY GRANULE; SECRETORY PATHWAY; SYMPATHETIC TONE;

AUTONOMIC PATHWAYS; BRAIN; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; MODELS, BIOLOGICAL; POLYMERIZATION; TIME FACTORS;

EID: 84890890049     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.002     Document Type: Article

References (72)

1. Butler A.E., Janson J., Bonner-Weir S., Ritzel R., Rizza R.A., Butler P.C. β-Cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
2. Porte D., Kahn S.E. Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes 2001, 50:S160.
3. Clark A., et al. Islet amyloid polypeptide in diabetic and non-diabetic pima indians. Diabetologia 1990, 33(5):285-289.
4. Westermark P., Wilander E., Westermark G.T., Johnson K.H. Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin-dependent) diabetic and non-diabetic individuals. Diabetologia 1987, 30:887-892.
5. Meier J.J. Beta cell mass in diabetes: a realistic therapeutic target?. Diabetologia 2008, 51:703-713.
6. Soong R., Brender J.R., Macdonald P.M., Ramamoorthy A. Association of highly compact type II diabetes related islet amyloid polypeptide intermediate species at physiological temperature revealed by diffusion NMR spectroscopy. J Am Chem Soc 2009, 131:7079-7085.
7. Höppener J.W.M., Ahrén B., Lips C.J.M. Islet amyloid and type 2 diabetes mellitus. N Engl J Med 2000, 343:411-419.
8. Haataja L., Gurlo T., Huang C.J., Butler P.C. Islet amyloid in type 2 diabetes, and the toxic oligomer hypothesis. Endocr Rev 2008, 29:303-316.
9. Demuro A., Mina E., Kayed R., Milton S.C., Parker I., Glabe C.G. Calcium dysregulation and membrane disruption as a ubiquitous neurotoxic mechanism of soluble amyloid oligomers. J Biol Chem. 2005, 280(17):17294-17300.
10. Janson J., Ashley R.H., Harrison D., McIntyre S., Butler P.C. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 1999, 48:491-498.
11. Konarkowska B., Aitken J.F., Kistler J., Zhang S., Cooper G.J.S. The aggregation potential of human amylin determines its cytotoxicity towards islet beta-cells. FEBS J 2006, 273:3614-3624.
12. Ritzel R.A., Butler P.C. Replication increases β-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. Diabetes 2003, 52:1701-1708.
13. Janson J., et al. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci 1996, 93(14):7283-7288.
14. Butler A.E., Janson J., Soeller W.C., Butler P.C. Increased β-cell apoptosis prevents adaptive increase in β-cell mass in mouse model of type 2 diabetes evidence for role of islet amyloid Formation rather than direct action of amyloid. Diabetes 2003, 52:2304-2314.
15. Lukinius A., Wilander E., Westermark G.T., Engström U., Westermark P. Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989, 32:240-244.
16. Hull R.L., Westermark G.T., Westermark P., Kahn S.E. Islet amyloid: a critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004, 89:3629-3643.
17. Johnson K.H., et al. Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein a-gold techniques. Am J Pathol 1988, 130(1):1-8.
18. Clark A., Chargé S.B., Badman M.K., de Koning E.J. Islet amyloid in type 2 (non-insulin-dependent) diabetes. APMIS Acta Pathol Microbiol Immunol Scand 1996, 104:12-18.
19. Nishi M., et al. Human islet amyloid polypeptide gene: complete nucleotide sequence, chromosomal localization, and evolutionary history. Mol Endocrinol Baltim Md 1989, 3(11):1775-1781.
20. Betsholtz C., et al. Islet amyloid polypeptide (IAPP):cDNA cloning and identification of an amyloidogenic region associated with the species-specific occurrence of age-related diabetes mellitus. Exp Cell Res 1989, 183(2):484-493.
21. Badman M.K., Shennan K.I.J., Jermany J.L., Docherty K., Clark A. Processing of pro-islet amyloid polypeptide (proIAPP) by the prohormone convertase PC2. FEBS Lett 1996, 378:227-231.
22. Higham C., et al. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) 'amylin' by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem FEBS 2000, 267(16):4998-5004.
23. Wang J., Xu J., Finnerty J., Furuta M., Steiner D.F., Verchere C.B. The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes. 2001, 50(3):534-539.
24. Bailyes E.M., et al. A member of the eukaryotic subtilisin family (PC3) has the enzymic properties of the type 1 proinsulin-converting endopeptidase. Biochem J 1992, 285(Pt 2):391-394.
25. Marzban L., et al. Role of β-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. Diabetes 2004, 53(1):141-148.
26. Westermark P., Andersson A., Westermark G.T. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011, 91:795-826.
27. Butler P.C., et al. Effects of meal ingestion on plasma amylin concentration in NIDDM and nondiabetic humans. Diabetes 1990, 39:752-756.
28. Qi D., et al. Fatty acids induce amylin expression and secretion by pancreatic β-cells. Am J Physiol - Endocrinol Metab 2010, 298(1):E99-E107.
29. Begg D.P., Woods S.C. Interactions between the central nervous system and pancreatic islet secretions: a historical perspective. Adv Physiol Educ 2013, 37:53-60.
30. Westermark P., Engstrom U., Johnson K.H., Westermark G.T., Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 1990, 87:5036-5040.
31. Betsholtz C., et al. Sequence divergence in a specific region of islet amyloid polypeptide (IAPP) explains differences in islet amyloid formation between species. FEBS Lett 1989, 251(1-2):261-264.
32. Esapa C., et al. Islet amyloid polypeptide gene promoter polymorphisms are not associated with type 2 diabetes or with the severity of islet amyloidosis. Biochim Biophys Acta 2005, 1740(1):74-78.
33. Cao P., et al. Islet amyloid: from fundamental biophysics to mechanisms of cytotoxicity. FEBS Lett 2013, 587(8):1106-1118.
34. Abedini A., Raleigh D.P. Destabilization of human IAPP amyloid fibrils by proline mutations outside of the putative amyloidogenic domain: is there a critical amyloidogenic domain in human IAPP?. J Mol Biol 2006, 355:274-281.
35. Koo B.W., Hebda J.A., Miranker A.D. Amide inequivalence in the fibrillar assembly of islet amyloid polypeptide. Protein Eng Des Sel PEDS 2008, 21:147-154.
36. Andrikopoulos S., Verchere C.B., Terauchi Y., Kadowaki T., Kahn S.E. Beta-cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 2000, 49:2056-2062.
37. Verchere C.B., D'Alessio D.A., Palmiter R.D., Kahn S.E. Transgenic mice overproducing islet amyloid polypeptide have increased insulin storage and secretion in vitro. Diabetologia 1994, 37:725-728.
38. Verchere C.B., et al. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 1996, 93(8):3492-3496.
39. Jaikaran E.T., Clark A. Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta 2001, 1537:179-203.
40. Gurlo T., et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol 2010, 176(2):861-869.
41. Krishnan R., et al. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc Natl Acad Sci USA 2012, 109(28):11172-11177.
42. Lin C.-Y., et al. Toxic human islet amyloid polypeptide (h-IAPP) oligomers are intracellular, and vaccination to induce anti-toxic oligomer antibodies does not prevent h-IAPP-induced β-Cell apoptosis in h-IAPP transgenic mice. Diabetes 2007, 56(5):1324-1332.
43. Song H., Ritz S., Knoll W., Sinner E.-K. Conformation and topology of amyloid beta-protein adsorbed on a tethered artificial membrane probed by surface plasmon field-enhanced fluorescence spectroscopy. J Struct Biol 2009, 168:117-124.
44. Kusumoto Y., Lomakin A., Teplow D.B., Benedek G.B. Temperature dependence of amyloid {beta}-protein fibrillization. Proc Natl Acad Sci 1998, 95:12277.
45. Marek P.J., Patsalo V., Green D.F., Raleigh D.P. Ionic strength effects on amyloid formation by amylin are a complicated interplay among Debye screening, ion selectivity, and Hofmeister effects. Biochem (Mosc) 2012, 51:8478-8490.
46. O'Brien T.D., Butler P.C., Westermark P., Johnson K.H. Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol 1993, 30:317-332.
47. Weyer C., Hanson R.L., Tataranni P.A., Bogardus C., Pratley R.E. A high fasting plasma insulin concentration predicts type 2 diabetes independent of insulin resistance: evidence for a pathogenic role of relative hyperinsulinemia. Diabetes 2000, 49:2094-2101.
48. Garvey W.T., Olefsky J.M., Marshall S. Insulin induces progressive insulin resistance in cultured rat adipocytes. Sequential effects at receptor and multiple postreceptor sites. Diabetes 1986, 35:258-267.
49. Dubuc P.U. The development of obesity, hyperinsulinemia, and hyperglycemia in ob/ob mice. Metabolism 1976, 25:1567-1574.
50. Dubuc P.U. Non-essential role of dietary factors in the development of diabetes in ob/ob mice. J Nutr 1981, 111:1742-1748.
51. Rohner-Jeanrenaud F., Jeanrenaud B. The central nervous system-endocrine pancreas axis. Ann Endocrinol 1983, 44:217-227.
52. Mako M.E., Starr J.I., Rubenstein A.H. Circulating proinsulin in patients with maturity onset diabetes. Am J Med 1977, 63:865-869.
53. Ben-Othman N., et al. From pancreatic islet formation to beta-cell regeneration. Diabetes Res Clin Pract 2013, 10.1016/j.diabres.2013.01.013.
54. Wang R.N., Bouwens L., Klöppel P.G. Beta-cell proliferation in normal and streptozotocin-treated newborn rats: site, dynamics and capacity. Diabetologia 1994, 37:1088-1096.
55. Kahn S.E., et al. Obesity, body fat distribution, insulin sensitivity and Islet beta-cell function as explanations for metabolic diversity. J Nutr 2001, 131(2):354S-360S.
56. Costes S., Langen R., Gurlo T., Matveyenko A.V., Butler P.C. β-cell failure in type 2 diabetes: a case of asking too much of too few?. Diabetes 2013, 62:327-335.
57. Watve M. Doves, diplomats, and diabetes: a Darwinian interpretation of type 2 diabetes and related disorders 2013, Springer.
58. Watve M.G., Yajnik C.S. Evolutionary origins of insulin resistance: a behavioral switch hypothesis. BMC Evol Biol 2007, 7:61.
59. Peters A., et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004, 28(2):143-180.
60. Gerozissis K. Brain insulin: regulation, mechanisms of action and functions. Cell Mol Neurobiol 2003, 23:1-25.
61. Biessels G.J., Bravenboer B., Gispen W.H. Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in health and disease: a preface. Eur J Pharmacol 2004, 490:1-4.
62. N'Guyen J.M., et al. Involvement of the autonomic nervous system in the in vivo memory to glucose of pancreatic beta cell in rats. J Clin Invest 1994, 94(4):1456-1462.
63. Del Rio G., et al. Cholinergic enhancement by pyridostigmine increases the insulin response to glucose load in obese patients but not in normal subjects. Int J Obes Relat Metab Disord J Int Assoc Study Obes 1997, 21(12):1111-1114.
64. Ahrén B., Simonsson E., Scheurink A.J., Mulder H., Myrsén U., Sundler F. Dissociated insulinotropic sensitivity to glucose and carbachol in high-fat diet-induced insulin resistance in C57BL/6J mice. Metabolism. 1997, 46(1):97-106.
65. Schaan B.D., Machado U.F. Glucose transporters in animal models of diabetes and hypertension. Am J Physiol - Ren Physiol 2006, 291:F702-F703.
66. Mitrani P., Srinivasan M., Dodds C., Patel M.S. Role of the autonomic nervous system in the development of hyperinsulinemia by high-carbohydrate formula feeding to neonatal rats. Am J Physiol Endocrinol Metab 2007, 292:E1069-1078.
67. Glasbrenner B., Dominguez-Munoz E., Riepl R.L., Vetsi A., Malfertheiner P. Cholecystokinin and pancreatic polypeptide release in diabetic patients with and without autonomic neuropathy. Dig Dis Sci 1995, 40:406-411.
68. Buysschaert M., Donckier J., Dive A., Ketelslegers J.M., Lambert A.E. Gastric acid and pancreatic polypeptide responses to sham feeding are impaired in diabetic subjects with autonomic neuropathy. Diabetes 1985, 34:1181-1185.
69. Kurose T., et al. Glucagon, insulin and somatostatin secretion in response to sympathetic neural activation in streptozotocin-induced diabetic rats. A study with the isolated perfused rat pancreas in vitro. Diabetologia 1992, 35(11):1035-1041.
70. Mu J., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 2006, 55(6):1695-1704.
71. Westermark G., et al. Amyloid formation in response to beta cell stress occurs in vitro, but not in vivo, in islets of transgenic mice expressing human islet amyloid polypeptide. Mol Med Camb Mass 1995, 1(5):542-553.
72. Henson M.S., et al. An in vitro model of early islet amyloid polypeptide (IAPP) fibrillogenesis using human IAPP-transgenic mouse islets. Amyloid Int J Exp Clin Investig Off J Int Soc Amyloidosis 2006, 13(4):250-259.